164 related articles for article (PubMed ID: 31828091)
21. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
22. OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.
Mao M; Huang RZ; Zheng J; Liang HQ; Huang WH; Liu J; Li JH
Cancer Med; 2021 Jan; 10(2):728-736. PubMed ID: 33405394
[TBL] [Abstract][Full Text] [Related]
23. Diffuse Sclerosing Papillary Thyroid Carcinoma: Clinicopathological Characteristics and Prognostic Implications Compared with Classic and Tall Cell Papillary Thyroid Cancer.
Scholfield DW; Fitzgerald CW; Alzumaili B; Eagan A; Xu B; Martinez G; Tuttle RM; Shaha AR; Shah JP; Wong RJ; Patel SG; Ghossein RA; Ganly I
Ann Surg Oncol; 2023 Aug; 30(8):4761-4770. PubMed ID: 37154968
[TBL] [Abstract][Full Text] [Related]
24. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
25. Expression of leptin and its receptor in thyroid carcinoma: distinctive prognostic significance in different subtypes.
Fan YL; Li XQ
Clin Endocrinol (Oxf); 2015 Aug; 83(2):261-7. PubMed ID: 25158596
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma.
Luo D; Liu Y; Lin S; Tan L; Du Z; Long M; Zhu Y; Peng X; Zong W; Mackenzie GG; Li H; Ouyang N
Oncol Rep; 2019 Feb; 41(2):1253-1263. PubMed ID: 30535496
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneous Prognoses for pT3 Papillary Thyroid Carcinomas and Impact of Delayed Risk Stratification.
Tavarelli M; Sarfati J; Chereau N; Tissier F; Golmard JL; Ghander C; Lussey-Lepoutre C; Trésallet C; Menegaux F; Leenhardt L; Buffet C
Thyroid; 2017 Jun; 27(6):778-786. PubMed ID: 28351220
[TBL] [Abstract][Full Text] [Related]
28. TFAP2B, AP-1 and JAZF1 Expression in Tissues of Papillary Thyroid Carcinoma Patients; Clinical, Pathological and Prognostic Values.
A Abuderman A; A Harb O; M Gertallah L; Makki Almansour N
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2415-2421. PubMed ID: 32856873
[TBL] [Abstract][Full Text] [Related]
29. Thyroid cancer in Egypt: histopathological criteria, correlation with survival and oestrogen receptor protein expression.
Ahmed RA; Aboelnaga EM
Pathol Oncol Res; 2015 Jul; 21(3):793-802. PubMed ID: 25576212
[TBL] [Abstract][Full Text] [Related]
30. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
32. Tumor keratin 15 expression links with less extent of invasion and better prognosis in papillary thyroid cancer patients receiving tumor resection.
Yang X; Liu Z; Wang X; Han Z; Zhang C; Guo L
Ir J Med Sci; 2024 Feb; 193(1):9-15. PubMed ID: 37243844
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients.
Wang W; Su X; He K; Wang Y; Wang H; Wang H; Zhao Y; Zhao W; Zarnegar R; Fahey TJ; Teng X; Teng L
Cancer; 2016 Jan; 122(2):198-206. PubMed ID: 26506214
[TBL] [Abstract][Full Text] [Related]
34. Implication of minimal extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma.
Shin JH; Ha TK; Park HK; Ahn MS; Kim KH; Bae KB; Kim TH; Choi CS; Kim TK; Bae SK; Kim SH
Int J Surg; 2013; 11(9):944-7. PubMed ID: 23820062
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological and prognostic significance of SHP2 and Hook1 expression in patients with thyroid carcinoma.
Cao J; Huang YQ; Jiao-Sun ; Lan XB; Ge MH
Hum Pathol; 2018 Nov; 81():105-112. PubMed ID: 29953894
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of Tiam1 expression in papillary thyroid carcinoma.
Hsueh C; Lin JD; Yang CF; Chang YS; Chao TC; Sun JH; Wu IC; Tseng NM; Ueng SH
Virchows Arch; 2011 Dec; 459(6):587-93. PubMed ID: 22075848
[TBL] [Abstract][Full Text] [Related]
37.
Luo J; Zhang B; Cui L; Liu T; Gu Y
Future Oncol; 2019 Apr; 15(12):1303-1311. PubMed ID: 30757917
[No Abstract] [Full Text] [Related]
38. Tripartite Motif Containing 3 inhibits the aggressive behaviors of papillary thyroid carcinoma and indicates lower recurrence risk.
Song Y; Gao Z; Yan Z; Zheng C
Genes Genomics; 2022 Apr; 44(4):455-465. PubMed ID: 34860317
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.
Kim WY; Kim HY; Son GS; Bae JW; Lee JB
J Cancer Res Ther; 2014; 10(1):50-5. PubMed ID: 24762486
[TBL] [Abstract][Full Text] [Related]
40. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
